Can you provide the last earnings date for DAY ONE BIOPHARMACEUTICALS I?
DAY ONE BIOPHARMACEUTICALS I (DAWN) last reported earnings on 2/24/2026.
DAY ONE BIOPHARMACEUTICALS I (DAWN) Earnings History & Surprises
NASDAQ:DAWN • US23954D1090
Current stock price
21.45 USD
+0.03 (+0.14%)
At close:
21.4 USD
-0.05 (-0.23%)
After Hours:
DAWN Earnings overview
Past quarterly earnings results for DAY ONE BIOPHARMACEUTICALS I (DAWN), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
Earnings Snapshot
Next Earnings Date
Upcoming- Release Date
- May 1, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$0.29
- Revenue Estimate
- 55.398M
Last Reported
Most Recent- Release Date
- Feb 24, 2026
- Period
- Q4 / 2025
- EPS Reported
- -$0.21
- EPS Surprise
- -35.56%
- Revenue Surprise
- 8.44%
Beat Rate
Last 8 Quarters 31%
EPS and Revenue beats vs estimates
Quarterly Earnings Historical Results
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | -0.21 | -0.15 | -35.56% | 67.19% | 53.718M | 49.538M | 8.44% | 83.97% |
| Q3 2025 | -0.19 | -0.30 | 36.38% | 48.65% | 39.795M | 38.964M | 2.13% | 98.28% |
| Q2 2025 | -0.29 | -0.36 | 20.33% | -480.00% | 33.908M | 36.007M | -5.83% | 313.92% |
| Q1 2025 | -0.35 | -0.45 | 22.45% | 51.39% | 30.761M | 30.842M | -0.26% | - |
| Q4 2024 | -0.64 | -0.37 | -73.33% | - | 29.2M | 28.348M | 3.01% | - |
| Q3 2024 | -0.37 | -0.42 | 11.53% | 31.48% | 20.07M | 24.016M | -16.43% | - |
| Q2 2024 | -0.05 | -0.77 | 93.47% | 91.80% | 8.192M | 1.042M | 686.18% | - |
| Q1 2024 | -0.72 | -0.68 | -6.41% | -22.03% | - | - | ||
| Q4 2023 | -0.64 | -0.59 | -7.56% | -14.29% | - | - | ||
| Q3 2023 | -0.54 | -0.61 | 12.11% | -1.89% | - | - | ||
| Q2 2023 | -0.61 | -0.62 | 1.98% | -1.67% | - | - | ||
| Q1 2023 | -0.59 | -0.60 | 2.33% | -22.92% | - | - | ||
| Q4 2022 | -0.56 | -0.58 | 3.12% | -55.56% | - | - | ||
| Q3 2022 | -0.53 | -0.54 | 2.70% | -60.61% | - | - | ||
| Q2 2022 | -0.60 | -0.50 | -20.66% | 88.10% | - | - | ||
| Q1 2022 | -0.48 | -0.39 | -22.23% | - | - | - | ||
| Q4 2021 | -0.36 | -0.36 | 1.28% | - | - | - | ||
| Q3 2021 | -0.33 | -0.29 | -15.44% | - | - | - | ||
| Q2 2021 | -5.04 | -0.32 | -1,468.63% | - | - | - | ||
| Q1 2021 | - | - | - | - | ||||
| Q4 2020 | - | - | - | - | ||||
| Q3 2020 | - | - | - | - | ||||
| Q2 2020 | - | - | - | - | ||||
| Q1 2020 | - | - | - | - |
Notes
- EPS and Revenue values are non-GAAP when available, otherwise GAAP.
- Surprise % is (Actual - Estimate) / |Estimate|. Green indicates positive surprise, red negative.
- Q2Q % is quarter-over-quarter growth. Green indicates growth, red indicates decline.
- Green right border indicates acceleration for sales or earnings growth. Acceleration is the case when the current Q2Q is above the previous Q2Q.
Earnings Q2Q Performance Trends
EPS Historical Q2Q growth and Acceleration
Revenue Historical Q2Q growth and Acceleration
Surprise distribution (Last 4 Quarters)
EPS beat statistics
EPS beat (4)
3
Average EPS beat (4)
10.90%
Max EPS beat (4)
36.38%
Min EPS beat (4)
-35.56%
Revenue beat statistics
Revenue beat (4)
2
Average Revenue beat (4)
1.12%
Max Revenue beat (4)
8.44%
Min Revenue beat (4)
-5.83%
Analysis
In the last 4 quarters, DAWN has beaten EPS estimates in 3 out of 4 releases
DAWN has beaten revenue estimates in 2 out of the last 4 releases
In the last 4 quarters, DAWN has beaten the EPS estimates by 10.9% on average.
In the last 4 quarters, DAWN has beaten the revenue estimates by 1.1% on average.
Related analysis
DAY ONE BIOPHARMACEUTICALS I / DAWN Earnings FAQ
Did DAWN stock beat earnings estimates in the most recent quarter?
DAY ONE BIOPHARMACEUTICALS I (DAWN) missed EPS estimates and beat revenue estimates in the most recent quarter.
How often does DAY ONE BIOPHARMACEUTICALS I (DAWN) beat earnings estimates?
In the last 4 quarters, DAY ONE BIOPHARMACEUTICALS I (DAWN) has beaten EPS estimates in 3 out of 4 releases.